Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.047018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Jheng-Yan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Chi Mei Medical Centre Tainan Taiwan. Hauptthemen laut MEDLINE: Tirzepatide, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
To evaluate the association between tirzepatide use and 1‐year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP‐1 (glucagon‐like peptide‐1) receptor agonists.
Methods
We conducted a retrospective, propensity score‐matched cohort study using the TriNetX network. A total of 16 402 patients with type 2 diabetes and atherosclerotic cardiovascular disease initiating tirzepatide or GLP‐1 receptor agonists between January 1, 2022, and March 31, 2025 were matched 1:1. The primary outcome was 1‐year major adverse cardiovascular events; secondary outcomes included all‐cause mortality, acute myocardial infarction, major adverse limb events, and tissue plasminogen activator use.
Results
Tirzepatide was associated with a lower risk of major adverse cardiovascular events (hazard ratio [HR], 0.75 [95% CI, 0.63–0.91]) and reduced risks of all‐cause mortality (HR, 0.69 [95% CI, 0.53–0.90]), major adverse limb events (HR, 0.59 [95% CI, 0.39–0.88]), and acute myocardial infarction (HR, 0.70 [95% CI, 0.53–0.93]), compared with GLP‐1 receptor agonists. Results were robust across subgroups and sensitivity analyses.
Conclusions
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a significantly reduced 1‐year risk of major adverse cardiovascular events and other cardiovascular outcomes compared with GLP‐1 receptor agonists. These findings support the cardiometabolic potential of tirzepatide, warranting further prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition Chi Mei Medical Centre Tainan Taiwan.
- Department of Public Health, College of Medicine National Cheng Kung University Tainan Taiwan.
- Division of Cardiology, Department of Internal Medicine Chi Mei Medical Centre, Chiali Tainan Taiwan.
- Department of Anesthesiology, E-Da Hospital I-Shou University Kaohsiung Taiwan.
- Department of Anesthesiology Chi Mei Medical Centre Tainan Taiwan.
- Division of Cardiology, Department of Internal Medicine Chi Mei Medical Centre Tainan Taiwan.
ORCID-Profile: Jheng-Yan Wu, Yu-Min Lin
Zitieren
APA
Wu, J. Y., Lee, K. W., Kao, C. L., Hung, K. C., Yu, T., & Lin, Y. M. (2026). Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047018
Vancouver
Wu JY, Lee KW, Kao CL, Hung KC, Yu T, Lin YM. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047018
BibTeX
@article{Wu2026,
author = {Wu, Jheng-Yan and Lee, Keng-Wei and Kao, Chia-Li and Hung, Kuo-Chuan and Yu, Tsung and Lin, Yu-Min},
title = {Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.047018}
}
EUVIMED